A skin anti-inflammatory, anti-wrinkle, and healing-promoting composition containing specific single-stranded DNA and its application

By using single-stranded DNA molecules with specific sequences to prepare skin care compositions, the problems of complex composition and poor batch stability of traditional PDRN mixtures are solved, achieving highly effective anti-inflammatory, anti-wrinkle and cell-healing effects on the skin, improving transdermal efficiency and reducing costs.

CN123107987APending Publication Date: 2026-11-17HARVEST BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610855305.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies often involve complex PDRN mixtures with poor batch stability and insufficient targeting, making it difficult to simultaneously and efficiently achieve skin anti-inflammation, anti-wrinkle effects, and deep cell repair, and also resulting in low transdermal efficiency.

Method used

Using a single-stranded DNA molecule with a specific sequence (as shown in SEQ ID NO:1), a skin care composition is prepared through precise adenosine A2A receptor binding and nucleotide rescue pathway, containing an effective amount of ssDNA-1 and cosmetically acceptable excipients for anti-inflammatory, anti-wrinkle and cell-healing effects on the skin.

Benefits of technology

It achieves highly effective anti-inflammatory, anti-wrinkle, and cell-healing effects, improves transdermal efficiency, reduces usage costs, has high safety, and is suitable for various dosage forms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107987A_ABST
    Figure CN123107987A_ABST
Patent Text Reader

Abstract

This invention relates to single-stranded DNA molecules and their application in skin care. The single-stranded DNA molecules have a defined base sequence and suitable molecular weight, making them suitable as novel PDRN functional components. The compositions of this invention exhibit significant anti-inflammatory and anti-wrinkle effects and promote cell / tissue healing, solving the problems of uneven composition and large batch-to-batch variations in traditional mixed PDRN formulations. They are characterized by high stability, clear efficacy, and mild, non-toxic side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedicine and cosmetics technology, specifically relating to a skin anti-inflammatory, anti-wrinkle, and healing-promoting composition containing specific single-stranded DNA and its application. Background Technology

[0002] Skin aging, chronic inflammation, and damage repair remain major challenges in the field of skin care. Traditional products often rely on chemically synthesized ingredients or large-molecule extracts, making it difficult to simultaneously and effectively achieve anti-inflammatory, anti-wrinkle, and deep cell repair effects. They also often suffer from low absorption rates, short-lasting effects, or potential irritation.

[0003] While polydeoxyribonucleotides (PDRNs) have shown anti-inflammatory effects, fibroblast proliferation promotion, and collagen synthesis enhancement through the adenosine A2A receptor pathway, traditional PDRNs are mostly mixed long-chain DNA fragments, resulting in complex compositions, significant batch-to-batch variations, and insufficient targeting. Currently, there is a lack of systematic research and optimized combinations for the specific applications of single-stranded DNA molecules in anti-inflammatory, anti-wrinkle, and healing-promoting skin treatments.

[0004] This invention screened and obtained a single-stranded DNA molecule with a specific sequence. After optimization of its molecular weight, sequence structure, and biological activity, it exhibited superior or complementary skin efficacy compared to traditional mixed PDRNs. This nucleic acid molecule achieves synergistic effects of highly efficient anti-inflammatory (inhibiting NF-κB, reducing pro-inflammatory factors), promoting collagen / elastin synthesis (anti-wrinkle), and accelerating cell / tissue healing through more precise receptor binding, nucleotide rescue pathways, and signaling pathway regulation. This solves the problems of uneven composition, unstable efficacy, and low transdermal efficiency in existing technologies. Summary of the Invention

[0005] This invention aims to solve the problems of complex composition, poor batch stability, insufficient targeting, and difficulty in simultaneously and efficiently achieving anti-inflammatory, anti-wrinkle, and deep cell repair effects of traditional PDRN mixtures in the prior art. It provides a skin care composition based on a specific single-stranded DNA molecule and its application.

[0006] In a first aspect, the present invention provides a nucleic acid molecule, wherein the nucleic acid molecule is the nucleic acid sequence shown in SEQ ID NO:1 or a nucleic acid sequence having 95%, 96%, 97%, 98%, or 99% or more of identity with SEQ ID NO:1; In some embodiments, the nucleic acid molecule is a nucleic acid molecule that has the functions of promoting cell proliferation, promoting skin repair, promoting skin wound healing, improving skin inflammation, promoting angiogenesis and / or increasing the content of vascular endothelial growth factor.

[0007] In some preferred embodiments, the nucleic acid molecule comprises a DNA molecule, specifically at least single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA).

[0008] In some preferred embodiments, the nucleic acid molecule is a DNA molecule, more preferably single-stranded DNA (ssDNA). The nucleic acid molecule has low methylation characteristics, contains a CpG motif, and its molecular weight is preferably 5 kDa to 300 kDa.

[0009] In some preferred embodiments, those skilled in the art can prepare the nucleic acid molecules using conventional methods, including but not limited to artificial synthesis, amplification, gene expression, or mutation.

[0010] Secondly, the present invention relates to a skin anti-inflammatory, anti-wrinkle, and cell-healing composition comprising an effective amount of ssDNA-1 as an active ingredient, and a pharmaceutically or cosmetically acceptable carrier or excipient. The ssDNA-1 is a single-stranded DNA molecule with a specific nucleotide sequence obtained through screening in this invention.

[0011] Preferably, the sequence of ssDNA-1 is as shown in SEQ ID NO:1 or is a nucleic acid sequence having 95%, 96%, 97%, 98%, or 99% or more identity with SEQ ID NO:1.

[0012] Preferably, the total content of active ingredients in the composition is 0.001 wt% to 5 wt%, more preferably 0.01 wt% to 2 wt%. The composition may further include one or more cosmetically or pharmaceutically acceptable excipients, such as hyaluronic acid and its salts, Centella asiatica extract, polypeptides, antioxidants, moisturizers, emulsifiers, penetration enhancers, etc.

[0013] Thirdly, the present invention provides the use of the above-mentioned nucleic acid molecules or compositions in the preparation of skin care products, the uses including but not limited to: anti-inflammatory effects on the skin, reduction of chronic inflammatory responses, reduction of fine lines and wrinkles, promotion of collagen and elastin synthesis, improvement of skin elasticity and firmness, acceleration of wound healing, promotion of cell repair, repair of skin barrier function, promotion of angiogenesis and increase of skin moisture content.

[0014] The products mentioned include, but are not limited to: cosmetics, skincare products, medical aesthetic products, pharmaceuticals, or medical devices. Specific dosage forms may include solutions, lotions, creams, gels, serums, lyophilized powders, masks, patches, injections, microneedle formulations, etc.

[0015] Fourthly, the present invention provides a kit comprising the above-mentioned nucleic acid molecules, the kit comprising one or more of the following components: (1) An effective amount of ssDNA-1 is provided as the active ingredient, preferably in the form of lyophilized powder, concentrate or stable solution; (2) Pharmaceutical or cosmetic acceptable carriers, solvents or diluents, such as physiological saline, phosphate buffer, hyaluronic acid solution or special compound solvents; (3) One or more excipient components selected from humectants, penetration enhancers, stabilizers, antioxidants or pH adjusters; (4) Instructions for use, which shall detail the indications, dosage, storage conditions and precautions of the kit; (5) Optionally, it also includes matching application tools, such as microneedle rollers, needle-free injection devices, mask base fabric, droppers or medical aesthetic syringes.

[0016] Compared with the prior art, the beneficial effects of the present invention are as follows: 1. Compared with traditional mixed PDRN, the specific sequence single-stranded DNA molecule of the present invention has the characteristics of well-defined sequence, high batch stability and easy purity control, avoiding the component difference problem common in natural extracts; 2. The single-stranded DNA can exert its anti-inflammatory (significantly inhibiting the NF-κB pathway and pro-inflammatory factor expression) and pro-synthetic (promoting fibroblast proliferation and extracellular matrix production) effects through more precise adenosine A2A receptor binding and nucleotide rescue pathway, thereby achieving multiple effects of anti-inflammatory, anti-wrinkle and healing promotion. 3. Single-stranded DNA can achieve better skin improvement effects at lower concentrations, which is beneficial for improving transdermal efficiency and reducing usage costs; 4. The composition of the present invention has high safety, low irritation, and wide applicability. It can be made into various dosage forms such as solutions, emulsions, creams, gels, serums, masks, and injections to meet the different needs of the cosmetics, medical aesthetics, and pharmaceutical fields. Attached Figure Description

[0017] Figure 1 This is the result of the PDRN single-stranded DNA molecule inflammatory factor NO content test; Figure 2 This is the result of a PDRN single-stranded DNA molecule type I collagen content test; Figure 3 It is a PDRN single-stranded DNA molecule keratinocyte scratch test; Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the present invention clearer, the present invention will be further described in detail below with reference to the accompanying drawings. The described embodiments should not be regarded as limitations on the present invention. All other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0019] Example 1: Screening of active single-stranded DNA sequences 1) Sample collection Spirulina samples were collected from high-salinity lakes at an altitude of over 4,000 meters.

[0020] 2) Genomic DNA extraction and library construction Genomic DNA was extracted from the collected Spirulina samples, and a DNA library was constructed.

[0021] 3) High-throughput sequencing and sequence assembly The constructed library was subjected to high-throughput sequencing to obtain sequencing reads, which were then assembled to obtain assembled DNA fragments.

[0022] 4) CpG motif screening and human genome alignment The assembled DNA fragments were pattern matched to obtain a 20 bp sequence containing the CpG motif (GTCGTT), which was then compared with the human genome sequence to remove sequences that highly overlapped with the human genome.

[0023] 5) PDRN function motif filtering Further screening yielded a natural single-stranded DNA fragment with a PDRN (polydeoxyribonucleotide) functional motif. From 653 candidate sequences, a specific sequence with significant biological activity was selected and named R33224-09 (SEQ ID NO:1). This ssDNA-1 is a naturally derived single-stranded DNA molecule containing a CpG motif, with a well-defined nucleotide sequence, a molecular weight within a suitable range for skin application, and no significant homology to the human genome, indicating high safety. Furthermore, another characteristic of this ssDNA is its low methylation, suggesting that the PDRN single-stranded DNA possesses stronger biological activity potential and immunomodulatory capabilities, enabling it to efficiently exert anti-inflammatory, repair-promoting, and regenerative effects while maintaining good biocompatibility. This is one of the important molecular bases for its use as a high-end skin repair ingredient.

[0024] The following molecules were obtained through screening experiments: Table 1: Sequences obtained through filtering name sequence length Remark R33224-09 TAGTGGGTCGTTCAAAAACT 20 SEQ ID NO:1

[0025] Example 2: Test of the soothing effect of PDRN single-stranded DNA molecules Experimental materials: Raw 264.7 cells Induction intensity: 200 ng / mL LPS, 24 h, with simultaneous induction and sample loading. Test samples: R33224-09 (1 ppm and 5 ppm); blank was the untreated cell group, negative control was the LPS-induced group. Positive control was 10 μg / mL DEX; Experimental method: ELISA Cell treatment involved inducing Raw264.7 macrophages with LPS and then culturing them for 24 hours. The levels of NO and TNF-α were then detected by ELISA (induction concentration: 200 ng / mL).

[0026] Experimental results (see) Figure 1 ): Compared with the blank control group, the content of inflammatory factor NO was significantly increased after cell induction with 200 ng / mL LPS, and the addition of 10 μg / mL DEX significantly increased the content of inflammatory factor NO. Compared with the negative control group, both 1 ppm and 5 ppm R33224-09 significantly inhibited the content of inflammatory factor NO. Therefore, under the experimental conditions, sample R33224-09 has a soothing effect. Example 3: Experiment on the firming and anti-wrinkle effects of PDRN single-stranded DNA molecules

[0027] Experimental materials: HSF cell relaxation test (induction intensity: 5 J / cm) 2 (Sample added after UVA induction) Experimental method: ELISA Test samples: R33224-09 (1ppm and 5ppm), blank was the untreated cell group, negative control was the UVA-induced group. Positive control was 100ng / mL TGF-β1; Cell treatment involved inducing fibroblast HSF cells with UVA followed by 24 h of culture, and then detecting Col I content using ELISA (induction intensity: 5 J / cm). 2 ).

[0028] Experimental results (see) Figure 2 ): Compared with the blank control group, 5J / cm 2 UVA-induced cells showed a significant decrease in type I collagen content, while the addition of 100 ng / mTGF-β1 significantly increased type I collagen content. Compared to the model group, both 1 ppm and 5 ppm of R33224-09 significantly increased type I collagen content. Under the experimental conditions, the tested sample R33224-09 consistently increased type I collagen content, demonstrating firming and anti-wrinkle effects.

[0029] Example 4: Keratinocyte scratch test

[0030] Experimental Methods: HaCaT Cell Barrier Repair Model Test groups: R33224-09 (1ppm and 5ppm) Positive control: 100 ng / mL TGF-β1 The specific experimental steps are as follows: The blank group was the scratch-damage treatment group. The positive control was 100 ng / mL TGF-β1; the cell treatment involved scratching keratinocytes (HaCaT) and then culturing them for 48 h, followed by measurement and calculation of the scratch repair rate using ImageJ software.

[0031] Experimental results (see) Figure 3 ): Compared with the blank control group, the addition of 100 ng / mL TGF-β1 significantly enhanced cell migration ability; 1 ppm R33224-09 significantly enhanced cell migration ability at 24 h and 48 h. Under the experimental conditions, R33224-09 significantly promoted keratinocyte healing compared with the control group.

[0032] Based on the above experimental evidence, the specific single-stranded DNA molecule provided by this invention exhibits significant multiple skin repair activities even at low concentrations of 1 ppm and 5 ppm. Specifically, in the LPS-induced Raw 264.7 macrophage inflammation model, it significantly reduces the release of the inflammatory factor nitric oxide (NO), demonstrating a good anti-inflammatory effect. In the UVA-induced HSF fibroblast photoaging model, samples at different concentrations significantly increase the content of type I collagen, exhibiting significant collagen synthesis-promoting and anti-wrinkle-firming effects. In the HaCaT keratinocyte scratch repair model, the sample significantly promotes cell migration and accelerates wound healing at different time points of 24 h and 48 h. These results fully demonstrate that the specific single-stranded DNA molecule of this invention possesses multiple biological activities, including highly efficient anti-inflammatory, anti-wrinkle, and cell / tissue-healing promotion, providing a solid experimental basis for the development of a new generation of safe and efficient skin repair compositions.

Claims

1. A nucleic acid molecule, characterized in that, The nucleic acid molecule is the nucleic acid sequence shown in SEQ ID NO:1 or a nucleic acid sequence that has more than 95% identity with SEQ ID NO:

1.

2. The nucleic acid molecule of claim 1, wherein, The nucleic acid molecule is a DNA molecule, preferably single-stranded DNA.

3. The nucleic acid molecule according to any one of claims 1 or 2, characterized in that, The molecular weight of the nucleic acid molecule is 5kDa to 300kDa.

4. The nucleic acid molecule of any one of claims 1-3, wherein, The nucleic acid molecules have biological functions such as promoting cell proliferation, improving skin inflammation, promoting skin repair, promoting wound healing, promoting angiogenesis, and / or increasing the content of vascular endothelial growth factor (VEGF).

5. A skin anti-inflammatory, anti-wrinkle and cell healing promoting composition, characterized in that, The active ingredient comprises an effective amount of any one of claims 1-4 nucleic acid molecules, and a pharmaceutically or cosmetically acceptable carrier or excipient.

6. The composition of claim 5, wherein, The active ingredient is ssDNA-1, whose nucleotide sequence is the sequence shown in SEQ ID NO:1 or a sequence having more than 95% identity with it. The total content of the active ingredient in the composition is 0.001wt% to 5wt%, preferably 0.01wt% to 2wt%.

7. The composition according to any one of claims 5-6, characterized in that, It also contains one or more excipients selected from hyaluronic acid and its salts, Centella asiatica extract, polypeptides, antioxidants, moisturizers, and penetration enhancers.

8. Use of the composition according to any one of claims 5-7 or the nucleic acid molecule according to any one of claims 1-4 in the preparation of skin care products.